Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

Last updated: January 15, 2013
Sponsor: Memorial Sloan Kettering Cancer Center
Overall Status: Completed

Phase

2

Condition

Urologic Cancer

Breast Cancer

Lung Disease

Treatment

N/A

Clinical Study ID

NCT00059943
01-136
MSKCC-01136
  • Ages > 65
  • All Genders

Study Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well docetaxel works in treating older patients with metastatic breast, lung, or prostate cancer.

Eligibility Criteria

Inclusion

DISEASE CHARACTERISTICS:

  • Histologically proven metastatic breast, lung, or prostate cancer

  • Measurable disease

  • No untreated CNS metastases

  • No symptomatic CNS metastases requiring escalating doses of corticosteroids

  • Hormone receptor status:

  • Not specified

PATIENT CHARACTERISTICS:

Age

  • 65 and over

Sex

  • Not specified

Menopausal status

  • Not specified

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified

Hematopoietic

  • Absolute neutrophil count at least 1,500/mm^3

  • Hemoglobin at least 8.0 g/dL

  • Platelet count at least 100,000/mm^3

Hepatic

  • Bilirubin normal

  • SGOT and/or SGPT no greater than 2.5 times upper limit of normal (ULN) with alkaline phosphatase no greater than ULN OR

  • Alkaline phosphatase no greater than 4 times ULN with SGOT and SGPT no greater than ULN

Renal

  • Not specified

Cardiovascular

  • No history of cardiac arrhythmia

  • No congestive heart failure

  • No myocardial infarction within the past 6 months

Other

  • No prior severe hypersensitivity reaction to docetaxel or other drugs containing polysorbate 80

  • No allergy to macrolide antibiotics

  • No grade 2 or greater peripheral neuropathy

  • No concurrent serious or uncontrolled infection

  • Able to read, write, and converse in English

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Recovered from prior chemotherapy

Endocrine therapy

  • See Disease Characteristics

Radiotherapy

  • Recovered from prior radiotherapy

Surgery

  • Not specified

Other

  • No concurrent CYP3A4-inducing or inhibiting medications or herbal remedies

  • No concurrent grapefruit juice

  • No concurrent ethanol

Study Design

Study Start date:
September 01, 2002
Estimated Completion Date:

Study Description

OBJECTIVES:

  • Determine the pharmacokinetics of docetaxel in older patients with metastatic breast, lung, or prostate cancer.

  • Determine the response of patients treated with this drug.

  • Determine the toxicity of this drug in these patients.

  • Determine the short-term changes in functional status, in terms of activities of daily living, independent activities of daily living, and Karnofsky performance status, in patients treated with this drug.

  • Correlate the number of comorbid conditions at baseline with declines in functional status in patients treated with this drug.

OUTLINE: Patients receive docetaxel IV over 30 minutes once weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 1 year.

Connect with a study center

  • Memorial Sloan-Kettering Cancer Center

    New York, New York 10021
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.